Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 11Gynecologic 5Thoracic 2Sarcoma 2Breast 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 8Breast Neoplasms 4Neoplasm Metastasis 3Cholangiocarcinoma 3Stomach Neoplasms 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Pancreatic Adenocarcinoma 1Neoplasms 1Mesothelioma 1Melanoma 1MMR-D/MSI-H Colorectal Cancers 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Anus Neoplasms 1

Interventions

Gemcitabine 69Fluorouracil 44pembrolizumab 43Oxaliplatin 42Capecitabine 40Bevacizumab 37Leucovorin 36Irinotecan 31Cisplatin 27Nivolumab 24Paclitaxel 21Cetuximab 21Panitumumab 20130-nm albumin-bound paclitaxel 20Sorafenib 18Albumin-Bound Paclitaxel 18Drug Therapy 15Docetaxel 15Cyclophosphamide 15Radiotherapy 14Blood Specimen Collection 14IFL protocol 12atezolizumab 11Exercise 11Taxes 10budigalimab 9Erlotinib Hydrochloride 9trametinib 8Folfox protocol 8Carboplatin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × niraparib × Gastrointestinal × Clear all
NCT03221400 2022-02-17

PEN-866 in Patients With Advanced Solid Malignancies

Tarveda Therapeutics

Phase 1/2 Unknown
340 enrolled
GastrointestinalThoracic

Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡